Cogent Biosciences director granted 17,901 stock options

Cogent Biosciences, Inc. director Karen Jean Ferrante received a new stock option grant covering 17,901 shares of common stock.

Rhea-AI Filing Summary

Cogent Biosciences, Inc. director Karen Jean Ferrante received a new stock option grant covering 17,901 shares of common stock. The option has an exercise price of $31.98 per share and expires on June 9, 2036.

According to the award terms, the option will vest in full on the earlier of the first anniversary of the grant date or the company’s 2027 Annual Meeting of Stockholders, provided she continues serving the company through that date. Following this grant, she holds 17,901 stock options directly.

Insider Trade Summary

Grant/Award: 17,901 shares

Grant/Award 1 txn

Insider Ferrante Karen Jean

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	17,901	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 17,901 contracts (Direct)

Footnotes (1)

1. F1. This stock option shall vest in full upon the earlier of the first anniversary of the date of grant or the date of the 2027 Annual Meeting of Stockholders, subject to the Reporting Person's continued service to the Issuer through such date.

Key Figures

Option grant size: 17,901 options Exercise price: $31.98 per share Expiration date: June 9, 2036 +1 more

4 metrics

Option grant size 17,901 options Stock Option (Right to Buy) granted to director

Exercise price $31.98 per share Stock option exercise price for Cogent Biosciences common stock

Expiration date June 9, 2036 Option expiration for granted stock options

Post-grant holdings 17,901 options Total derivative securities following this transaction

Key Terms

Stock Option (Right to Buy), exercise price, vesting, Annual Meeting of Stockholders

4 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

exercise price financial

"conversion_or_exercise_price: 31.9800"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"This stock option shall vest in full upon the earlier of the first anniversary"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

Annual Meeting of Stockholders financial

"earlier of the first anniversary of the date of grant or the date of the 2027 Annual Meeting of Stockholders"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Karen Jean Ferrante acquire in this Cogent Biosciences (COGT) Form 4?

Karen Jean Ferrante received a stock option grant for 17,901 shares of Cogent Biosciences common stock. The option is a compensation award, not an open-market purchase, and gives her the right to buy shares at a fixed exercise price.

What is the exercise price of the new Cogent Biosciences (COGT) stock options?

The granted stock options have an exercise price of $31.98 per share. This means Ferrante can buy Cogent Biosciences common stock at $31.98 once the options vest, regardless of the market price at that future time.

When do Karen Jean Ferrante’s Cogent Biosciences (COGT) options vest?

The options vest in full on the earlier of the first anniversary of the grant date or the 2027 Annual Meeting of Stockholders. Vesting is conditional on her continued service to Cogent Biosciences through that vesting date.

When do the newly granted Cogent Biosciences (COGT) stock options expire?

The stock options expire on June 9, 2036. After that expiration date, Ferrante can no longer exercise the options to purchase Cogent Biosciences common stock, even if they are fully vested and previously exercisable.

How many Cogent Biosciences (COGT) options does Ferrante hold after this grant?

Following this transaction, Ferrante holds 17,901 stock options directly. This figure reflects the total number of derivative securities reported in the Form 4 after the award, all tied to Cogent Biosciences common stock.

Is this Cogent Biosciences (COGT) Form 4 an open-market stock purchase or sale?

No, this Form 4 reports a grant of stock options as compensation, not an open-market trade. The transaction code “A” indicates a grant or award acquisition, with no shares bought or sold on the public market.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/11/2026 - 04:30 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ferrante Karen Jean

(Last) (First) (Middle)

C/O COGENT BIOSCIENCES, INC.

180 THIRD AVENUE, 4TH FLOOR

(Street)

WALTHAM MASSACHUSETTS 02451

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Cogent Biosciences, Inc. [ COGT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/09/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$31.98	06/09/2026		A		17,901		(1)	06/09/2036	Common Stock	17,901	$0	17,901	D

Explanation of Responses:

1. This stock option shall vest in full upon the earlier of the first anniversary of the date of grant or the date of the 2027 Annual Meeting of Stockholders, subject to the Reporting Person's continued service to the Issuer through such date.

	/s/ Evan D. Kearns, Attorney-in-Fact	06/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)